First of a new breed of anticancer antibodies approved in Japan


The first in a new class of immune-oncology drugs has been approved for use in Japan. Ono pharmaceuticals’ Opdivo (nivolumab) has been approved for treating melanomas where surgery is impossible.

Nivolumab is part of a new wave of cancer therapies that encourage our immune systems to fight cancers or enhance their performance. It targets programmed cell death (PD1) receptors that are expressed on tumour cell surfaces to ward off detection by the immune system.

Ono developed the monoclonal antibody in conjunction with US biotech Medarex, which was acquired by Bristol-Myers Squib (BMS) in 2009. BMS is developing the drug outside of Japan, Korea and Taiwan.


Related Content

First biosimilar antibody drugs approved in Europe

11 September 2013 Business

news image

European commission gives final approval to generic infliximab copies

Business roundup

29 September 2011 Business

news image

Industry news, October 2011

Most Read

Linguistic statistics enable synthetic prophetics

17 July 2014 Research

news image

A metric more commonly used by search engines to analyse language can now power organic chemistry retrosyntheses

Coffee cup confusion

20 July 2014 Research

news image

Scientists call for better labelling after research highlights inconsistencies in the chemical composition of a cup of coffee

Most Commented

Royal Society of Chemistry's flagship journal now free to access

16 July 2014 News and Analysis

news image

Chemical Science will follow gold open access model from January 2015 and waive author fees for two years

Coffee cup confusion

20 July 2014 Research

news image

Scientists call for better labelling after research highlights inconsistencies in the chemical composition of a cup of coffee